GLOW and KLOW: composition comparison

KLOW contains everything GLOW contains, plus KPV. GHK-Cu, BPC-157 and TB-500 are named on both listings; KPV appears only on KLOW's.

KPV is a tripeptide — lysine, proline, valine — corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone. It is the shortest peptide in the HEEZ catalogue, and it is what distinguishes the two blends compositionally.

The three shared components are unchanged in identity between the blends. GHK-Cu is a copper-complexed tripeptide, BPC-157 a fifteen-residue linear peptide, TB-500 a synthetic fragment related to thymosin beta-4.

GLOW is 70 mg and KLOW is 80 mg, and the arithmetic invites a conclusion: that the extra 10 mg is KPV. That inference is not supported by any published figure.

Neither listing publishes a per-component split. The quantities of GHK-Cu, BPC-157 and TB-500 within KLOW's 80 mg are not stated and are not necessarily the same as their quantities within GLOW's 70 mg. Both the composition of the shared portion and the mass of the added component are unpublished.

This matters for any protocol requiring a known quantity of a specific peptide. Where component-level quantities are needed, each of the four components is stocked separately in the catalogue with its own certificate of analysis, and those single-compound listings are the appropriate source.

By contrast the Wolverine blend does publish its split — 5 mg BPC-157 and 5 mg TB-500 in a 10 mg vial — which shows that disclosure is a per-product decision rather than a general policy about blends.

Reconstitution arithmetic for a blend runs against the total vial mass. GLOW at 70 mg reconstituted with 2 ml gives 35 mg per ml of blended material; KLOW at 80 mg with the same 2 ml gives 40 mg per ml.

Those figures describe the blend as a whole. Because no split is published, a component-specific concentration cannot be derived from them, and calculating one would mean supplying a number that has not been stated.

Both blends contain GHK-Cu, so both inherit its light sensitivity. Copper peptides are more susceptible to light than unmodified peptides, which makes storage in the dark a specific requirement rather than general good practice.

A multi-component solution is only as stable as its least stable component, so the shortest applicable window governs how long reconstituted material is held.

A certificate for a blend covers the blended material as supplied, for one specific batch. As with any batch-specific document, the first check is that its lot number matches the vial in hand.

Reading one differs from reading a single-compound certificate in a way worth being explicit about. A three- or four-component chromatogram shows multiple principal peaks by design, not one main peak with impurities beside it. The single purity percentage that characterises a single compound therefore does not translate — there is no one peak for it to describe.

What a blend certificate does confirm is that the named components are present and identifiable. For protocols that require a quantified amount of a specific peptide, that confirmation is not sufficient on its own, because identity is not quantity.

Each of the four components — GHK-Cu, BPC-157, TB-500 and KPV — is stocked separately in the catalogue with its own single-compound certificate. Where component-level documentation matters, those listings are the appropriate reference rather than either blend.